AFNI Message Board

Dear AFNI users-

We are very pleased to announce that the new AFNI Message Board framework is up! Please join us at:

https://discuss.afni.nimh.nih.gov

Existing user accounts have been migrated, so returning users can login by requesting a password reset. New users can create accounts, as well, through a standard account creation process. Please note that these setup emails might initially go to spam folders (esp. for NIH users!), so please check those locations in the beginning.

The current Message Board discussion threads have been migrated to the new framework. The current Message Board will remain visible, but read-only, for a little while.

Sincerely, AFNI HQ

History of AFNI updates  

Previous Message Next Message
Message List New Topic Print View
|
gang
May 28, 2020 04:14PM
Just as subjects are samples from a hypothetical population pool, so trials in an FMRI experiment are instantiations from a condition category. If cross-subject variability should be properly accounted for, why would cross-trial variability not be on an equal footing? In addition to improving generalizability, capturing trial-level effects may also gain estimation accuracy and statistical sensitivity. The analytical tool at the whole-brain voxel level is already available: 3dLMEr.

[www.biorxiv.org]

Gang
Reply Quote
RSS
Subject Author Posted

Should BOLD response be modeled at the trial level?

gang May 28, 2020 04:14PM

Re: Should BOLD response be modeled at the trial level?

ptaylor May 28, 2020 04:40PM

Re: Should BOLD response be modeled at the trial level?

gang May 28, 2020 07:39PM

Re: Should BOLD response be modeled at the trial level?

ptaylor May 29, 2020 11:26AM

Re: Should BOLD response be modeled at the trial level?

nmuncy July 14, 2020 11:54AM

Re: Should BOLD response be modeled at the trial level?

gang July 15, 2020 09:13AM